A “patent cliff” refers to the end of IP protection for a drug that has enjoyed market exclusivity since its launch. Various types of regulatory exclusivity can occasionally lengthen the protection for drugs, but generally...more
Many patent owners have not yet had to defend against an inter partes review (IPR), but the popularity of this proceeding increases the chances that they will encounter it down the road if they have not already faced one....more
6/1/2016
/ America Invents Act ,
Broadest Reasonable Interpretation Standard ,
Claim Construction ,
Corporate Counsel ,
Estoppel ,
Inter Partes Review (IPR) Proceeding ,
Patent Applications ,
Patent Owner Preliminary Response ,
Patent Portfolios ,
Patent Trial and Appeal Board ,
Reissue Patents ,
Request for Continued Examination ,
USPTO